Update 2003: FDA and CLIA
description
Transcript of Update 2003: FDA and CLIA
![Page 1: Update 2003: FDA and CLIA](https://reader035.fdocuments.in/reader035/viewer/2022062217/568139b6550346895da1533f/html5/thumbnails/1.jpg)
1
Update 2003: FDA and CLIA Update 2003: FDA and CLIA Update 2003: FDA and CLIA Update 2003: FDA and CLIA
Clara A. Sliva, MT(ASCP), MPA
Acting CLIA Coordinator
FDA
IVD Roundtable 510(k) Workshop
April 22, 2003
IVD Roundtable 510(k) Workshop
April 22, 2003
![Page 2: Update 2003: FDA and CLIA](https://reader035.fdocuments.in/reader035/viewer/2022062217/568139b6550346895da1533f/html5/thumbnails/2.jpg)
2
Surviving CLIASurviving CLIASurviving CLIASurviving CLIA
CLIA Overview --Something OLD --Something NEW Key Features Who are the players FDA and CLIA CLIA regulations What is categorization What requires categorization What is not regulated under CLIA
![Page 3: Update 2003: FDA and CLIA](https://reader035.fdocuments.in/reader035/viewer/2022062217/568139b6550346895da1533f/html5/thumbnails/3.jpg)
3
Surviving CLIASurviving CLIASurviving CLIASurviving CLIA
How FDA categorizes tests
-CDRH
-CBER “Automatic” categorizations Specific requests for categorizations Categorization letter; CLIA website Where do you go for help
![Page 4: Update 2003: FDA and CLIA](https://reader035.fdocuments.in/reader035/viewer/2022062217/568139b6550346895da1533f/html5/thumbnails/4.jpg)
4
What is CLIA?What is CLIA?What is CLIA?What is CLIA? Clinical Laboratory Improvement
Amendments of 1988 (CLIA) Enacted as result of reports of inaccurate
test results from Pap smears Questions were raised about how labs
functioned and what quality control procedures existed
![Page 5: Update 2003: FDA and CLIA](https://reader035.fdocuments.in/reader035/viewer/2022062217/568139b6550346895da1533f/html5/thumbnails/5.jpg)
5
CLIA’88 - President Reagan- 10/31/1988 Social Security Act Labs receiving Medicare funds must be CLIA-
certified. All clinical labs must be CLIA-certified to test
human specimens Notice Proposed Rule 1990/60,000 comments Final Rule 2/28/1992 Final QC Rule 1/24/03
CLIA ‘88CLIA ‘88CLIA ‘88CLIA ‘88
![Page 6: Update 2003: FDA and CLIA](https://reader035.fdocuments.in/reader035/viewer/2022062217/568139b6550346895da1533f/html5/thumbnails/6.jpg)
6
Highlights Final QC RuleHighlights Final QC RuleHighlights Final QC RuleHighlights Final QC Rule
Removes FDA’s review of manufacturers' QC instructions for compliance with CLIA
Sets QC standards for nonwaived testing. Reduces QC frequency in most of the
subspecialties Merges moderate & high complexity QC
requirements Uses plain language
![Page 7: Update 2003: FDA and CLIA](https://reader035.fdocuments.in/reader035/viewer/2022062217/568139b6550346895da1533f/html5/thumbnails/7.jpg)
7
Highlights Highlights Highlights Highlights
Reorganizes to mimic the flow of a specimen through the lab.
Studies show most lab errors are pre-analytical
Requires mod. complexity labs to validate a test once before use
Ensures the test works accurately before pts. tested.
Onus on laboratory CMS drafting inspector guidelines
![Page 8: Update 2003: FDA and CLIA](https://reader035.fdocuments.in/reader035/viewer/2022062217/568139b6550346895da1533f/html5/thumbnails/8.jpg)
8
Who are the Players?Who are the Players? Who are the Players?Who are the Players?
Centers for Medicare and Medicaid Services (formerly HCFA) oversees CLIA
Authority for regulation and policy CLIA self-funded User fees from regulated labs CMS pays FDA to categorize commercially
marketed tests CDC categorizes lab procedures -Provider performed microscopy -Gram stain
![Page 9: Update 2003: FDA and CLIA](https://reader035.fdocuments.in/reader035/viewer/2022062217/568139b6550346895da1533f/html5/thumbnails/9.jpg)
9
CMS CMS CMS CMS
Reimbursement CLIA certificate HIPAA – Privacy Act CLIA regulations, lab sends report to authorized
person CLIA defines as individual authorized under State
law to order tests or receive test results, or both. HIPAA-- patient requests their records from a lab,
results should be sent to them.
![Page 10: Update 2003: FDA and CLIA](https://reader035.fdocuments.in/reader035/viewer/2022062217/568139b6550346895da1533f/html5/thumbnails/10.jpg)
10
CMS CLIA ContactCMS CLIA ContactCMS CLIA ContactCMS CLIA Contact
Kathy Todd, CMS [email protected]
Phone: 410.786.3385 Fax: 410.786.1224
![Page 11: Update 2003: FDA and CLIA](https://reader035.fdocuments.in/reader035/viewer/2022062217/568139b6550346895da1533f/html5/thumbnails/11.jpg)
11
OIVD’s CLIA PlayersOIVD’s CLIA PlayersOIVD’s CLIA PlayersOIVD’s CLIA Players
Renita Hoard, CSO Dr. Joe Hackett, founding father Don St. Pierre, Deputy Director Dr. Steve Gutman, Director CLIA team – represents OIVD CBER devices – Clara CBER waiver tests- Clara, lead reviewer,
OIVD CLIA team
![Page 12: Update 2003: FDA and CLIA](https://reader035.fdocuments.in/reader035/viewer/2022062217/568139b6550346895da1533f/html5/thumbnails/12.jpg)
12
Key FeaturesKey FeaturesKey FeaturesKey Features
Standards based on complexity of testing, not the laboratory site
The key to understanding categorization;
-the analyst/operator
-how complex it is for the analyst to run the test
![Page 13: Update 2003: FDA and CLIA](https://reader035.fdocuments.in/reader035/viewer/2022062217/568139b6550346895da1533f/html5/thumbnails/13.jpg)
13
FDA and CLIAFDA and CLIAFDA and CLIAFDA and CLIA
1992 CLIA regulations FDA responsible for complexity
categorization 1993-94 FDA categorized >900 tests 1994 CDC delegated responsibility Resources, funding issues
![Page 14: Update 2003: FDA and CLIA](https://reader035.fdocuments.in/reader035/viewer/2022062217/568139b6550346895da1533f/html5/thumbnails/14.jpg)
14
FDA and CLIAFDA and CLIAFDA and CLIAFDA and CLIA
Impetus for change Manufacturers Congress “Confusion and duplication of effort” CDC, CMS, FDA consensus Interagency agreement 2/27/99 Tri-agency team – CMS, CDC, FDA
![Page 15: Update 2003: FDA and CLIA](https://reader035.fdocuments.in/reader035/viewer/2022062217/568139b6550346895da1533f/html5/thumbnails/15.jpg)
15
What Regulations Govern What Regulations Govern CategorizationCategorization
What Regulations Govern What Regulations Govern CategorizationCategorization
42 CFR 493.17, categorization of specific laboratory tests by level of complexity
Moderate, high 7 Criteria
![Page 16: Update 2003: FDA and CLIA](https://reader035.fdocuments.in/reader035/viewer/2022062217/568139b6550346895da1533f/html5/thumbnails/16.jpg)
16
Moderate, HighModerate, HighModerate, HighModerate, High
42 CFR 493.17• Knowledge• Training and experience• Characteristics of operational Steps• Calibration, QC, PT materials• Troubleshooting, Maintenance• Interpretation and judgment
![Page 17: Update 2003: FDA and CLIA](https://reader035.fdocuments.in/reader035/viewer/2022062217/568139b6550346895da1533f/html5/thumbnails/17.jpg)
17
Moderate, HighModerate, HighModerate, HighModerate, High
42 CFR 493.17• 7 criteria scored as 1, 2, or 3• Score of 1 = minimum • Score of 3 = specialized• Total scores of 12 or less = moderate• 13 or higher = high • e.g. PCR = high complexity
![Page 18: Update 2003: FDA and CLIA](https://reader035.fdocuments.in/reader035/viewer/2022062217/568139b6550346895da1533f/html5/thumbnails/18.jpg)
18
Categorization RegulationsCategorization RegulationsCategorization RegulationsCategorization Regulations
42 CFR 493.15 (c) Lists the 9 generic test groups Categorized by regulation Automatically waived But still requires categorization
notification letter from FDA Requires posting categorization on
website
![Page 19: Update 2003: FDA and CLIA](https://reader035.fdocuments.in/reader035/viewer/2022062217/568139b6550346895da1533f/html5/thumbnails/19.jpg)
19
Generic 9Generic 9Generic 9Generic 9493.15 (c)dipstick and tablet reagent urinalysis fecal occult blood ovulation tests urine pregnancy tests erythrocyte sedimentation rate hemoglobin (copper sulfate) blood glucose devices (FDA-cleared for OTC use) spun microhematocrit hemoglobin single analyte instruments (1993)
![Page 20: Update 2003: FDA and CLIA](https://reader035.fdocuments.in/reader035/viewer/2022062217/568139b6550346895da1533f/html5/thumbnails/20.jpg)
20
Most Common Waived TestsMost Common Waived TestsMost Common Waived TestsMost Common Waived Tests
Urine pregnancy – 34% All other tests – 20% Blood glucose (OTC) – 18% Urine dipstick/tablet chemistries-19% Ovulation tests – 5% Fecal occult blood – 4%
![Page 21: Update 2003: FDA and CLIA](https://reader035.fdocuments.in/reader035/viewer/2022062217/568139b6550346895da1533f/html5/thumbnails/21.jpg)
21
Categorization RegulationsCategorization RegulationsCategorization RegulationsCategorization Regulations
CMS and PHS Sept 13, 1995 Notice of Proposed Rulemaking
Clarified statutory criteria for obtaining waiver
Guidelines list the criteria Final rule pending CMS leads tri-agency team
![Page 22: Update 2003: FDA and CLIA](https://reader035.fdocuments.in/reader035/viewer/2022062217/568139b6550346895da1533f/html5/thumbnails/22.jpg)
22
CMS/PHS Waiver CriteriaCMS/PHS Waiver CriteriaCMS/PHS Waiver CriteriaCMS/PHS Waiver Criteria
Defined simplicity, low risk Defined accuracy as comparison to
reference materials, methods Precision field studies in hands of
lay user Flex studies, different environments Studies distinct from FDA premarket
review
![Page 23: Update 2003: FDA and CLIA](https://reader035.fdocuments.in/reader035/viewer/2022062217/568139b6550346895da1533f/html5/thumbnails/23.jpg)
23
Categorization RegulationsCategorization RegulationsCategorization RegulationsCategorization Regulations
Food and Drug Modernization Act Nov. 21, 1997
clarifies tests cleared for over-the-counter are automatically waived.
But still requires categorization notification letter from FDA
Requires posting categorization on website
![Page 24: Update 2003: FDA and CLIA](https://reader035.fdocuments.in/reader035/viewer/2022062217/568139b6550346895da1533f/html5/thumbnails/24.jpg)
24
OTCOTCOTCOTC
Growing number of OTC tests -drugs of abuse -cholesterol, HDL chol -vaginal ph -microalbumin -FSH, qual. -HgbA1C -fern test, saliva. -semen, male fertility
![Page 25: Update 2003: FDA and CLIA](https://reader035.fdocuments.in/reader035/viewer/2022062217/568139b6550346895da1533f/html5/thumbnails/25.jpg)
25
Prescription Home UsePrescription Home UsePrescription Home UsePrescription Home Use
Prescription home use is an Rx device physician instructs patient to use in home
FDA devices are OTC or Rx Any device used in the home that is
not OTC Examples – prothrombin time,
hemoglobin A1c
![Page 26: Update 2003: FDA and CLIA](https://reader035.fdocuments.in/reader035/viewer/2022062217/568139b6550346895da1533f/html5/thumbnails/26.jpg)
26
What is Categorization?What is Categorization?What is Categorization?What is Categorization?
Process of assigning new commercially marketed tests to one of 3 CLIA categories: waived, moderate, high
The key to understanding categorization; the analyst/operator and the complexity of testing
Regulations that govern categorization
![Page 27: Update 2003: FDA and CLIA](https://reader035.fdocuments.in/reader035/viewer/2022062217/568139b6550346895da1533f/html5/thumbnails/27.jpg)
27
What Requires What Requires CategorizationCategorizationWhat Requires What Requires CategorizationCategorization
Categorization applies to all laboratory test systems on materials derived from the human body conducted for the purpose of diagnosis, prevention or treatment, or assessment of the health
![Page 28: Update 2003: FDA and CLIA](https://reader035.fdocuments.in/reader035/viewer/2022062217/568139b6550346895da1533f/html5/thumbnails/28.jpg)
28
What Requires What Requires CategorizationCategorizationWhat Requires What Requires CategorizationCategorization
Plain Language Commercially marketed test systems
that produce a result This includes 510(k) exempt tests
![Page 29: Update 2003: FDA and CLIA](https://reader035.fdocuments.in/reader035/viewer/2022062217/568139b6550346895da1533f/html5/thumbnails/29.jpg)
29
Not CategorizedNot Categorized Not CategorizedNot Categorized
Produce no test result Quality Control Calibrators Test tubes Collection kits
--drugs of abuse
--Hepatitis C, HIV
![Page 30: Update 2003: FDA and CLIA](https://reader035.fdocuments.in/reader035/viewer/2022062217/568139b6550346895da1533f/html5/thumbnails/30.jpg)
30
Not Categorized Not Categorized Not Categorized Not Categorized
Not currently regulated under CLIA Non-invasive (laser hematocrit) Breath tests (h. pylori, alcohol) Drugs of abuse – Workplace Monitoring devices (Minimed)
![Page 31: Update 2003: FDA and CLIA](https://reader035.fdocuments.in/reader035/viewer/2022062217/568139b6550346895da1533f/html5/thumbnails/31.jpg)
31
How FDA CategorizesHow FDA CategorizesHow FDA CategorizesHow FDA Categorizes
Center for Devices and Radiological Health
Center for Biologics Evaluation and Research
![Page 32: Update 2003: FDA and CLIA](https://reader035.fdocuments.in/reader035/viewer/2022062217/568139b6550346895da1533f/html5/thumbnails/32.jpg)
32
CDRH CategorizesCDRH CategorizesCDRH CategorizesCDRH Categorizes
Pre-amendment 510(k) exempt tests New Premarket Notification 510(k)
e.g. special 510(k)s New Premarket Approvals (original,
supplements)
![Page 33: Update 2003: FDA and CLIA](https://reader035.fdocuments.in/reader035/viewer/2022062217/568139b6550346895da1533f/html5/thumbnails/33.jpg)
33
CDRH CategorizesCDRH CategorizesCDRH CategorizesCDRH Categorizes
New Humanitarian Device Exemptions (original, supplement)
510(k) add-to-files -Replacement reagents -Manufacturer name change -Relabel Previously uncategorized test
systems
![Page 34: Update 2003: FDA and CLIA](https://reader035.fdocuments.in/reader035/viewer/2022062217/568139b6550346895da1533f/html5/thumbnails/34.jpg)
34
Automatic CategorizationsAutomatic CategorizationsAutomatic CategorizationsAutomatic Categorizations
Manufacturer submits premarket submission to Document Mail Center
Categorization performed in conjunction with product review
CLIA notification accompanies clearance, approval order or follows shortly after
![Page 35: Update 2003: FDA and CLIA](https://reader035.fdocuments.in/reader035/viewer/2022062217/568139b6550346895da1533f/html5/thumbnails/35.jpg)
35
Automatic Categorization, Automatic Categorization, Replacement ReagentsReplacement Reagents
Automatic Categorization, Automatic Categorization, Replacement ReagentsReplacement Reagents
Well characterized lab analyzers for use by laboratory professionals.
Previously cleared instruments and reagents, when a claim is made for a new reagent/instrument combination.
Introduction of new instrument family members of a previously cleared instrument family.
![Page 36: Update 2003: FDA and CLIA](https://reader035.fdocuments.in/reader035/viewer/2022062217/568139b6550346895da1533f/html5/thumbnails/36.jpg)
36
Automatic CategorizationAutomatic CategorizationAutomatic CategorizationAutomatic Categorization
Replacement reagent• Replacement reagents require a package
insert with the new instrument/reagent combination
• CLIA notification follows shortly after
![Page 37: Update 2003: FDA and CLIA](https://reader035.fdocuments.in/reader035/viewer/2022062217/568139b6550346895da1533f/html5/thumbnails/37.jpg)
37
Categorization by RequestCategorization by RequestCategorization by RequestCategorization by Request
Change in company name Additional trade name Modification? Not previously categorized
-defaults to high complexity
![Page 38: Update 2003: FDA and CLIA](https://reader035.fdocuments.in/reader035/viewer/2022062217/568139b6550346895da1533f/html5/thumbnails/38.jpg)
38
Categorization by RequestCategorization by RequestCategorization by RequestCategorization by Request
Submit new labeling to FDA Document Mail Center, HFZ-401, 9200
Corporate Blvd., Rockville, MD 20850 “For CLIA Categorization Only” Reference original 510(k) number CLIA categorization performed Notification letter to manufacturer Categorization posted on website
![Page 39: Update 2003: FDA and CLIA](https://reader035.fdocuments.in/reader035/viewer/2022062217/568139b6550346895da1533f/html5/thumbnails/39.jpg)
39
Categorization by RequestCategorization by RequestCategorization by RequestCategorization by Request
Exempt from 510(k), CLIA required Submit new labeling to FDA’s DMC “For CLIA Categorization Only” OIVD assigns “X” document number
![Page 40: Update 2003: FDA and CLIA](https://reader035.fdocuments.in/reader035/viewer/2022062217/568139b6550346895da1533f/html5/thumbnails/40.jpg)
40
Categorization by RequestCategorization by RequestCategorization by RequestCategorization by Request
“X” number accessible through CLIA database
CLIA categorization performed CLIA letter issued Categorization posted on CLIA
website
![Page 41: Update 2003: FDA and CLIA](https://reader035.fdocuments.in/reader035/viewer/2022062217/568139b6550346895da1533f/html5/thumbnails/41.jpg)
41
Categorization by RequestCategorization by RequestCategorization by RequestCategorization by Request
Waiver via CMS/PHS 1995 Criteria Test cleared or approved to apply for
waiver through process FDA approves waiver protocol Waiver studies begin Timeframe depends on queue
![Page 42: Update 2003: FDA and CLIA](https://reader035.fdocuments.in/reader035/viewer/2022062217/568139b6550346895da1533f/html5/thumbnails/42.jpg)
42
CBER:CBER:CBER:CBER:
Manufacturer submits request for product review to CBER
When test is cleared, approved, licensed CBER sends test instructions to Clara Sliva
CBER test logged into CDRH CLIA database using CBER document number: BK, BP, BLA, PL
![Page 43: Update 2003: FDA and CLIA](https://reader035.fdocuments.in/reader035/viewer/2022062217/568139b6550346895da1533f/html5/thumbnails/43.jpg)
43
Rapid HIV WaiverRapid HIV WaiverRapid HIV WaiverRapid HIV Waiver
Manufacturer submits waiver application to CDRH
CBER reviewer consults CMS consults CDRH issues letter CDRH posts categorization on CLIA
website
![Page 44: Update 2003: FDA and CLIA](https://reader035.fdocuments.in/reader035/viewer/2022062217/568139b6550346895da1533f/html5/thumbnails/44.jpg)
44
Categorization Notification Categorization Notification LetterLetter
Categorization Notification Categorization Notification LetterLetter
FDA’s document number is the key “k001111” – new 510(k) CDRH “BLA002222 – new BLA CBER “k001111/A1” – new trade name complexity test system name analyte name
![Page 45: Update 2003: FDA and CLIA](https://reader035.fdocuments.in/reader035/viewer/2022062217/568139b6550346895da1533f/html5/thumbnails/45.jpg)
45
Categorization Notification Categorization Notification LetterLetter
Categorization Notification Categorization Notification LetterLetter
Call – don’t be shy No letter 3 weeks after clearance Incorrect letter Website updates monthly
![Page 46: Update 2003: FDA and CLIA](https://reader035.fdocuments.in/reader035/viewer/2022062217/568139b6550346895da1533f/html5/thumbnails/46.jpg)
46
FDA’s CLIA Workload FDA’s CLIA Workload FDA’s CLIA Workload FDA’s CLIA Workload
10/1//02 – 4/18/03 1,125 categorized 912 - moderate 87 - high 126 - waived
![Page 47: Update 2003: FDA and CLIA](https://reader035.fdocuments.in/reader035/viewer/2022062217/568139b6550346895da1533f/html5/thumbnails/47.jpg)
47
>1,125 Tests Categorized>1,125 Tests Categorized>1,125 Tests Categorized>1,125 Tests Categorized
0%
10%
20%
30%
40%
50%
60%
70%
ModerateHIGHWAIVED
![Page 48: Update 2003: FDA and CLIA](https://reader035.fdocuments.in/reader035/viewer/2022062217/568139b6550346895da1533f/html5/thumbnails/48.jpg)
48
FDA’s CLIA WebsiteFDA’s CLIA WebsiteFDA’s CLIA WebsiteFDA’s CLIA Website
http://www.fda.gov/cdrh/clia/ “Government Google” for current
CLIA information Lists all waived analytes and tests Links to CMS, CDC websites CLIA database
![Page 49: Update 2003: FDA and CLIA](https://reader035.fdocuments.in/reader035/viewer/2022062217/568139b6550346895da1533f/html5/thumbnails/49.jpg)
49
CLIA DatabaseCLIA DatabaseCLIA DatabaseCLIA Database
http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfCLIA/search.cfm
Contains all commercially marketed tests categorized by CDC and FDA
Several ways to search
![Page 50: Update 2003: FDA and CLIA](https://reader035.fdocuments.in/reader035/viewer/2022062217/568139b6550346895da1533f/html5/thumbnails/50.jpg)
50
Search CLIA DatabaseSearch CLIA DatabaseSearch CLIA DatabaseSearch CLIA Database
Search for CLIA records by -test system name -specialty/subspecialty -analyte -document number -qualifier (reagent application) e.g. SLIVA Analyzer/St. Pierre reagent -effective date -complexity
![Page 51: Update 2003: FDA and CLIA](https://reader035.fdocuments.in/reader035/viewer/2022062217/568139b6550346895da1533f/html5/thumbnails/51.jpg)
51
TipsTipsTipsTips
• You may enter the entire test name• But most successful if you enter the
first word or two• Or just the first few letters• e.g. first few letters of manufacturer
name
![Page 52: Update 2003: FDA and CLIA](https://reader035.fdocuments.in/reader035/viewer/2022062217/568139b6550346895da1533f/html5/thumbnails/52.jpg)
52
Mastering the CLIA DatabaseMastering the CLIA DatabaseMastering the CLIA DatabaseMastering the CLIA Database
Manufacturer Test System Qualifier Analyte Document Number Complexity Analyte Specialty Effective Date (mm/dd/yyyy) Sort one or a combination of the values and
select Search:
![Page 53: Update 2003: FDA and CLIA](https://reader035.fdocuments.in/reader035/viewer/2022062217/568139b6550346895da1533f/html5/thumbnails/53.jpg)
53
Publication of Publication of CategorizationsCategorizationsPublication of Publication of
CategorizationsCategorizations
Monthly on FDA’s CLIA Home Page Federal Register Notice, interval to
be determined
![Page 54: Update 2003: FDA and CLIA](https://reader035.fdocuments.in/reader035/viewer/2022062217/568139b6550346895da1533f/html5/thumbnails/54.jpg)
54
What We Have LearnedWhat We Have LearnedWhat We Have LearnedWhat We Have Learned
Multiple stakeholders Labs Providers Patients Manufacturers Government
![Page 55: Update 2003: FDA and CLIA](https://reader035.fdocuments.in/reader035/viewer/2022062217/568139b6550346895da1533f/html5/thumbnails/55.jpg)
55
Over 31,000 CategorizationsOver 31,000 CategorizationsOver 31,000 CategorizationsOver 31,000 Categorizations
Laboratory Inspectors, Laboratories, Manufacturers, and Other Stakeholders
Want to Know
![Page 56: Update 2003: FDA and CLIA](https://reader035.fdocuments.in/reader035/viewer/2022062217/568139b6550346895da1533f/html5/thumbnails/56.jpg)
56
CLIA INFORMATION CLIA INFORMATION CLIA INFORMATION CLIA INFORMATION
Clara A.R. Sliva http://www.fda.gov/cdrh/clia [email protected] phone (301) 827-0496 fax (301)827-1401